← Back to Home

BB-301 Gene Therapy Shows Signs of Improved Swallowing, with Nine Oculopharyngeal Muscular Dystrophy Patients Meeting Response Criteria

A single local administration aims to improve progressively declining swallowing function. All nine patients in an early BB-301 trial met company-defined response criteria, but only three received the high dose, and there was no control group. Efficacy and durability still require confirmation in larger studies.

By SURL BioNews

As swallowing muscles gradually weaken, a sip of water or a meal can become a daily challenge. On October 28, Benitec Biopharma announced an update from an early human trial of its gene therapy BB-301 for swallowing difficulties caused by oculopharyngeal muscular dystrophy (OPMD): all nine treated patients met the company-defined response criteria. This provides preliminary evidence for the treatment, but is not yet sufficient to establish efficacy.

The Phase 1b/2a trial uses an open-label, dose-escalation design with no control group. All six low-dose patients have completed 12 months of post-treatment follow-up. Among the three high-dose patients, one has nine months of data, while the other two have only three months of follow-up. The common time point at which all patients in both groups can be directly compared is therefore three months after administration.

At this time point, the high-dose group showed higher response rates on some swallowing measures. When pharyngeal emptying was assessed by examining food and liquid residue through videofluoroscopy, 67% of the low-dose group and 100% of the high-dose group met the response criteria. For functional swallowing ability assessed using a timed cold-water drinking test, the corresponding rates were 17% and 67%. However, with only three patients in the high-dose group, a single patient's results can substantially change the percentages. These findings cannot currently establish that the higher dose is more effective.

Other measures also remind readers that “all patients responded” should not be interpreted as a complete restoration of swallowing function. RTTNews reported that at month three, 100% of patients in both groups met the response criteria on the patient-completed Sydney Swallow Questionnaire. However, when pharyngeal closure was assessed through videofluoroscopy, the rate was 67% in both groups. These percentages represent the proportion of patients meeting specific thresholds, rather than the magnitude of improvement in each patient.

OPMD is a rare inherited muscle disease associated with mutations in the PABPN1 gene. Weakening of the pharyngeal muscles makes swallowing increasingly difficult. BB-301 uses a “silence and replace” strategy: a modified AAV9 viral vector delivers both RNA interference components that suppress abnormal PABPN1 expression and a replacement gene capable of producing a functional protein into the pharyngeal muscles involved in swallowing. The therapy is administered locally once, with the aim of acting at the site of disease.

Benitec said that no patients receiving BB-301 have experienced serious adverse events to date, and that improvements in the low-dose group have persisted through longer follow-up. However, safety experience in nine patients remains limited and cannot rule out rare or later-emerging risks. BioPharm International also noted that response was determined using company-defined statistical criteria and that the results have not yet been published in a peer-reviewed journal. The open-label design and lack of a control group also limit the ability to attribute efficacy to the treatment.

These data have been accepted for presentation at the annual meeting of the European Society of Gene and Cell Therapy. Benitec plans to initiate a pivotal trial in mid-2027, but the final design remains subject to confirmation with the U.S. Food and Drug Administration. The next stage will need to determine whether these swallowing improvements can be reproduced in a more rigorous comparison and how long the effects of a single treatment can last.

References

  1. Benitec Biopharma / SEC
  2. BioPharm International
  3. RTTNews